TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02403115

Intervention type: OTHER
Intervention: Serum collection
Description: Clinical tests (renal function, complete blood count, CRP, ANA, dsDNA, urinalysis) will be performed at fixed time intervals (6, 12, 24 and 36 months) and the surplus of blood sample will form the serum bank used for the study

Intervention type: OTHER
Intervention: Serum collection
Description: Clinical tests (renal function, complete blood count, CRP, ANA, dsDNA, urinalysis) will be performed at fixed time intervals (6, 12, 24 and 36 months) and the surplus of blood sample will form the serum bank used for the study
Study: NCT02484703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5186582
Description: Participants will receive 1 of 3 dosages of RO5186582 PO BID, including 40 mg, 60 mg, or 120 mg. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5186582
Description: Participants will receive 1 of 3 dosages of RO5186582 PO BID, including 40 mg, 60 mg, or 120 mg. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5186582
Description: Participants will receive 1 of 3 dosages of RO5186582 PO BID, including 40 mg, 60 mg, or 120 mg. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
Study: NCT03416400

Intervention type: OTHER
Intervention: Oocyte vitrification
Description: Immature oocytes were collected from patients (≤37 years old, without endometriosis, Polycystic syndrome or other ovulatory desease) who underwent to ICSI. In addition, immature oocytes collected from patient diagnosed with cancer will be included in this study. Oocytes were matured in vitro with IVM medium and vitrified in closed system (Vitrolife). Kinetic of maturation were analyzed by Primovision (Vitrolife) and actin, and spindle organization were studied by microscopy, immunostaining techniques and quantitive analysis.

Intervention type: OTHER
Intervention: Oocyte vitrification
Description: Immature oocytes were collected from patients (≤37 years old, without endometriosis, Polycystic syndrome or other ovulatory desease) who underwent to ICSI. In addition, immature oocytes collected from patient diagnosed with cancer will be included in this study. Oocytes were matured in vitro with IVM medium and vitrified in closed system (Vitrolife). Kinetic of maturation were analyzed by Primovision (Vitrolife) and actin, and spindle organization were studied by microscopy, immunostaining techniques and quantitive analysis.

Intervention type: OTHER
Intervention: Oocyte vitrification
Description: Immature oocytes were collected from patients (≤37 years old, without endometriosis, Polycystic syndrome or other ovulatory desease) who underwent to ICSI. In addition, immature oocytes collected from patient diagnosed with cancer will be included in this study. Oocytes were matured in vitro with IVM medium and vitrified in closed system (Vitrolife). Kinetic of maturation were analyzed by Primovision (Vitrolife) and actin, and spindle organization were studied by microscopy, immunostaining techniques and quantitive analysis.
Study: NCT00098111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine
Study: NCT03759067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel 75mg
Description: clopidogrel once daily 75mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel 75mg
Description: clopidogrel once daily 75mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 300 mg
Description: clopidogrel 300mg reloading

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel 600mg
Description: clopidogrel 600mg loading
Study: NCT00262067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients received bevacizumab until disease progression, treatment limiting toxicity, or death due to any cause up to a maximum treatment duration of 48 months. The dose of bevacizumab was based on the patient's weight at either screening or baseline and remained the same throughout the blinded treatment phase of the study. The initial dose was delivered over 90±10 minutes. If there were no infusion related adverse events (fever and/or chills), the second infusion was delivered over 60±10 minutes. If the 60 minute infusion was well tolerated, all subsequent infusions were delivered over 30±10 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consisted of the vehicle for bevacizumab without the antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles.~Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle~1. Docetaxel 75-100 mg/m\^2 IV~2. Paclitaxel protein-bound particles (Abraxane®) 260 mg/m\^2 IV~Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle~1. 5-fluorouracil 500 mg/m\^2 IV + epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~2. 5-fluorouracil 500 mg/m\^2 IV + doxorubicin 50 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~3. Doxorubicin 50-60 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~4. Epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~Capecitabine: 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles.~Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle~1. Docetaxel 75-100 mg/m\^2 IV~2. Paclitaxel protein-bound particles (Abraxane®) 260 mg/m\^2 IV~Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle~1. 5-fluorouracil 500 mg/m\^2 IV + epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~2. 5-fluorouracil 500 mg/m\^2 IV + doxorubicin 50 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~3. Doxorubicin 50-60 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~4. Epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~Capecitabine: 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle
Study: NCT01735981

Intervention type: OTHER
Group type: OTHER
Intervention: Video game exercise using Dance Dance Revolution
Description: use of the video-game, Dance, Dance Revolution as an exercise to improve gait and balance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video game exercise using Dance Dance Revolution
Description: use of the video-game, Dance, Dance Revolution as an exercise to improve gait and balance
Study: NCT01547416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose
Description: Before the induction of anesthesia, epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. .~Epidural analgesia was maintained using the patient-controlled analgesia technique containing 250 mL of 0.2% ropivacaine and 2 μg/mL fentanyl with setting of 5 mL/hr for continuous infusion and 0.5 mL of bolus dose. Lockout time was set to 15 min.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: no epidural drug administered
Description: Patients allocated to general anesthesia group and DID NOT receive epidural anesthesia.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg.
Study: NCT01266213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus Goserelin
Description: Fulvestrant s.c. plus Goserelin s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus Goserelin
Description: Fulvestrant s.c. plus Goserelin s.c.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant plus Goserelin
Description: Fulvestrant s.c. plus Goserelin s.c.
Study: NCT01609608

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: whole body vibration
Description: to deliver mechanical oscillation to individuals at various frequencies, amplitudes, and accelerations for different durations. This technique has been applied for years to enhance strength, and improve bone mineral density and balance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: whole body vibration
Description: to deliver mechanical oscillation to individuals at various frequencies, amplitudes, and accelerations for different durations. This technique has been applied for years to enhance strength, and improve bone mineral density and balance
Study: NCT02164058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TandemHeart System

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Study: NCT05491902

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: Scans will be performed on a 1.5T Philips scanner including a 3D T1-weighted scan for co-registration with PET scans and rating of hippocampal atrophy, as well as standard T1 and T2-weighted sequences for rating of white matter lesions.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: Scans will be performed on a 1.5T Philips scanner including a 3D T1-weighted scan for co-registration with PET scans and rating of hippocampal atrophy, as well as standard T1 and T2-weighted sequences for rating of white matter lesions.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: Scans will be performed on a 1.5T Philips scanner including a 3D T1-weighted scan for co-registration with PET scans and rating of hippocampal atrophy, as well as standard T1 and T2-weighted sequences for rating of white matter lesions.
Study: NCT01735981

Intervention type: OTHER
Group type: OTHER
Intervention: hand-held video game
Description: hand-held video games

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand-held video game
Description: hand-held video games
Study: NCT01901952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive education and lifestyle support
Description: Group classes for 12 months (weekly for 4 months, biweekly for 4 months, monthly for 4 months), weekly peer supporter telephone calls, and diabetes education newsletters every 2 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care control group
Description: Participants receive 2 diabetes education classes taught by a Certified Diabetes Educator. They also receive diabetes education newsletters every 2 months.
Study: NCT05847023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LUNA
Description: see description above

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LUNA
Description: see description above
Study: NCT03133208

Intervention type: PROCEDURE
Intervention: Blood draws
Description: Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72 (7 draws total). Each draw would be up to 20 mL of blood (but no less than 10 mL).

Intervention type: PROCEDURE
Intervention: Blood draws
Description: Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72 (7 draws total). Each draw would be up to 20 mL of blood (but no less than 10 mL).

Intervention type: PROCEDURE
Intervention: Blood draws
Description: Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72 (7 draws total). Each draw would be up to 20 mL of blood (but no less than 10 mL).
Study: NCT04311294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANS-6637 Low Dose
Description: ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANS-6637 High Dose
Description: ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
Study: NCT00459355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Safety Toolkit
Description: Health literacy-verified booklet and home safety items to promote competence to make home safety modifications.
Study: NCT04474171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCI&U online health coaching program
Description: Online secure videoconferencing health coaching platform with resource library to promote self-management. Maximum number of sessions is 14 over 6 months and covers health related topics to reduce secondary complications
Study: NCT02864576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation_Aerobic Exercise
Description: Cognitive Remediation:~The REHACOP program consists of: Attention unit training sustained, selective, alternant and divided attention; Memory unit focusing on visual and verbal learning, recall and recognizing memory; Language unit including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit training cognitive planning, proverbs, analogies; and Social cognition unit exercising theory of mind, social reasoning and moral dilemmas.~Aerobic Exercise:~12 weeks of systematic aerobic exercise program. Patients will walk with a moderate intensity 10 minutes the first week and will increase gradually up to 30 minutes-walk with a moderate intensity. Patients will also perform 5 minutes of warm-up and stretching.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation_Health Promotion
Description: Cognitive Remediation:~The REHACOP program consists of: Attention unit training sustained, selective, alternant and divided attention; Memory unit focusing on visual and verbal learning, recall and recognizing memory; Language unit including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit training cognitive planning, proverbs, analogies; and Social cognition unit exercising theory of mind, social reasoning and moral dilemmas.~Health Promotion:~12 weeks of health promotion sessions. These sessions will be carried out by a specialized/trained nurse.
Study: NCT00766740

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thrombectomy devices
Description: mechanical or manual devices able to remove thrombus from the coronary arteries.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: angioplasty
Description: percutaneous coronary angioplasty with use of balloon catheters and bare metal stents or drug eluting stents.
Study: NCT02955212

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets for oral administration
Study: NCT01519310

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic (metronidazole and ciprofloxacin)/probiotic
Description: Antibiotic cocktail/yogurt as follows:~Group 1: antibiotics for 1 week, followed by probiotics for 3 weeks; Group 2: antibiotics for 1 week, followed by no probiotics for 3 weeks. Group 3: no antibiotics for 1 week, followed by probiotics for 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic (metronidazole and ciprofloxacin)/probiotic
Description: Antibiotic cocktail/yogurt as follows:~Group 1: antibiotics for 1 week, followed by probiotics for 3 weeks; Group 2: antibiotics for 1 week, followed by no probiotics for 3 weeks. Group 3: no antibiotics for 1 week, followed by probiotics for 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic (metronidazole and ciprofloxacin)/probiotic
Description: Antibiotic cocktail/yogurt as follows:~Group 1: antibiotics for 1 week, followed by probiotics for 3 weeks; Group 2: antibiotics for 1 week, followed by no probiotics for 3 weeks. Group 3: no antibiotics for 1 week, followed by probiotics for 3 weeks.
Study: NCT03223350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin 0.1% Cream
Description: Topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo cream
Study: NCT04365010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate Ringer's Injection
Description: For each month of the trial, participating ICUs were assigned to use either Sodium Bicarbonate Ringer's Injection or 0.9% Saline for any intravenous administration of isotonic crystalloid. ICUs were randomly assigned to use Sodium Bicarbonate Ringer's Injection during even-numbered months and 0.9% Saline during odd-numbered months, or vice versa.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: For each month of the trial, participating ICUs were assigned to use either Sodium Bicarbonate Ringer's Injection or 0.9% Saline for any intravenous administration of isotonic crystalloid. ICUs were randomly assigned to use Sodium Bicarbonate Ringer's Injection during even-numbered months and 0.9% Saline during odd-numbered months, or vice versa.
Study: NCT03288064

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corinthian currant
Description: Supplementation of 1.5 g CHO/kg BW in the form of Corinthian currant prior to exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose drink
Description: Supplementation of 1.5 g CHO/kg BW in the form of glucose drink prior to exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water ingestion
Description: Supplementation of 7ml/kg BW prior to exercise
Study: NCT01121250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Discussion Groups
Description: Each telephone discussion group will meet 12 times during six months. The one-hour calls will be semi-structured conference calls with education, training in coping skills and cognitive restructuring, and support. A Participant Workbook will include comprehensive materials for all sessions and topics, other resources, and red flag resources - areas that may exacerbate problems, add a level of difficulty or distress, and/or indicate a need for referrals (e.g., unsafe behaviors, substance abuse, spouse abuse, PTSD, depression, traumatic brain injury).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education sessions
Description: Participants will have 12 sessions (delivered using slides and telephone) that cover the same education content, without skills building or support, over six months. They will also receive the Participant Workbook.
Study: NCT02365987

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Interesterified blend of palm kernal and plam stearin
Description: 50g fat provided as interesterified palm kernal and palm sterin blend in a single meal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Un-interesterified blend of palm kernal and plam stearin
Description: 50g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal
Study: NCT02517008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mama kit
Description: A low-cost non-monetary incentive (mama kit) was provided to all women who delivered at the facility between June 1, 2013 - Aug 31, 2013. Women were told about the intervention during ANC, and safe motherhood groups in the community promoted the intervention in the catchment areas of the treatment facilities.
Study: NCT01306305

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V
Description: Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2010-2011 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus~* 15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V
Description: Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2010-2011 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus~* 15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1
Study: NCT00208442

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marathon™
Description: Moderately cross-linked polyethylene liner in a modular acetabular component

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enduron
Description: Standard polyethylene liner in a modular acetabular component
Study: NCT00312338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIGAMOX
Description: 1 drop of VIGAMOX® ophthalmic solution 0.5% in both eyes TID for 7 days